Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments.

ABSTRACT:

SUBMITTER: Gower A 

PROVIDER: S-EPMC9834586 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature